INCEPTIONR LLC: CHRW position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of INCEPTIONR LLC on CHRW, newest first. How the timeline and the estimate are built.
INCEPTIONR LLC held 0 CHRW shares at 2025-12-31 per its 13F-HR filed 2026-02-11.
the latest 13F is the newest step
- period ended2025-12-3113F 0 sharesChange vs previous 13F -3,195 shares
13F-HR 0002085853-26-000252 filed by INCEPTIONR LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2025-09-3013F 3,195 sharesChange vs previous 13F -8,359 shares
0.1% of the 13F portfolio, value $423,018.
13F-HR 0002085853-25-000272 filed by INCEPTIONR LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-06-3013F 11,554 sharesChange vs previous 13F +5,393 shares
0.26% of the 13F portfolio, value $1,108,606.
13F-HR 0001667731-25-001097 filed by INCEPTIONR LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-03-3113F 6,161 sharesChange vs previous 13F +6,161 shares
0.19% of the 13F portfolio, value $630,886.
13F-HR 0001667731-25-000611 filed by INCEPTIONR LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-12-3113F 0 sharesChange vs previous 13F -4,521 shares
13F-HR 0001667731-25-000215 filed by INCEPTIONR LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2024-09-3013F 4,521 sharesChange vs previous 13F not available
0.12% of the 13F portfolio, value $498,983.
13F-HR 0001821561-24-000008 filed by INCEPTIONR LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).